Endurance Time During Constant Work Rate Cycle Ergometry in COPD: Development of an Integrated Database From Interventional Studies.
bronchodilator
clinical outcome assessment
exercise endurance
exercise training
patient-centric
Journal
Chronic obstructive pulmonary diseases (Miami, Fla.)
ISSN: 2372-952X
Titre abrégé: Chronic Obstr Pulm Dis
Pays: United States
ID NLM: 101635411
Informations de publication
Date de publication:
26 Oct 2022
26 Oct 2022
Historique:
pubmed:
7
9
2022
medline:
7
9
2022
entrez:
6
9
2022
Statut:
ppublish
Résumé
The COPD Biomarkers Qualification Consortium (CBQC) was formed under COPD Foundation management, with the goal of qualifying biomarkers and clinical outcome assessments through established regulatory processes for chronic obstructive pulmonary disease (COPD). Within CBQC, a working group evaluated opportunities for qualification of an exercise endurance measure. In a recent publication ( We sought participant-level data from published studies incorporating CWRCE as an outcome measure. A literature search screened 2993 publications and identified 553 studies for assessment. Two interventions had sufficient data across studies to warrant data extraction: bronchodilators and rehabilitative exercise training. Investigators were contacted and requested to provide participant-by-participant data from their published studies. The final dataset included data from 8 bronchodilator studies (2166) participants and 15 exercise training studies (3488 participants). The database includes 71 variables per participant, comprising demographic, pulmonary function, and detailed physiologic response data. This paper provides a detailed description of the analysis population, while analysis supporting the validation/qualification process and addressing other scientific questions will be described in subsequent publications.
Identifiants
pubmed: 36066494
doi: 10.15326/jcopdf.2022.0331
pmc: PMC9718584
doi:
Types de publication
Journal Article
Langues
eng
Pagination
520-537Subventions
Organisme : Boehringer Ingelheim
Pays : Germany
Organisme : GlaxoSmithKline
Pays : United Kingdom
Organisme : Novartis
Pays : Switzerland
Organisme : AstraZeneca
Pays : United Kingdom
Organisme : Chiesi
Pays : Italy
Informations de copyright
JCOPDF © 2022.
Références
Eur Respir J. 2017 Apr 19;49(4):
pubmed: 28424359
Am Rev Respir Dis. 1991 Jan;143(1):9-18
pubmed: 1986689
Am J Respir Crit Care Med. 1997 May;155(5):1541-51
pubmed: 9154855
Braz J Phys Ther. 2016 Jan 19;20(2):105-13
pubmed: 26786084
Eur Respir J Suppl. 1993 Mar;16:5-40
pubmed: 8499054
Ann Intern Med. 2008 Dec 16;149(12):869-78
pubmed: 19075206
Eur Respir J. 2013 Oct;42(4):982-92
pubmed: 23429918
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465818755091
pubmed: 29439648
Eur Respir J. 2015 Dec;46(6):1625-35
pubmed: 26453626
Eur Respir J. 2009 Oct;34(4):866-74
pubmed: 19282342
Int J Chron Obstruct Pulmon Dis. 2011;6:647-57
pubmed: 22162650
COPD. 2013 Aug;10(4):425-35
pubmed: 23537344
Respir Med. 2011 Apr;105(4):580-7
pubmed: 21183326
Thorax. 2008 Feb;63(2):115-21
pubmed: 17901158
Eur Respir J. 2009 Aug;34(2):340-5
pubmed: 19251787
Lung. 2006 May-Jun;184(3):159-67
pubmed: 16902841
COPD. 2013 Jun;10(3):367-77
pubmed: 23713597
J Cardiopulm Rehabil. 2003 Mar-Apr;23(2):143-50
pubmed: 12668937
Am J Respir Crit Care Med. 2003 Nov 1;168(9):1034-42
pubmed: 12869359
Respiration. 2003 Jul-Aug;70(4):367-70
pubmed: 14512671
Chronic Obstr Pulm Dis. 2022 Apr 29;9(2):252-265
pubmed: 35018752
BMC Pulm Med. 2014 Dec 23;14:209
pubmed: 25539654
Respirology. 2015 Oct;20(7):1089-95
pubmed: 26148453
Chest. 2006 Sep;130(3):647-56
pubmed: 16963658
Respir Res. 2016 Jul 06;17(1):77
pubmed: 27383762
Eur Respir J. 2016 Feb;47(2):429-60
pubmed: 26797036
Digit Biomark. 2020 Sep 15;4(3):69-77
pubmed: 33083687
Am J Respir Crit Care Med. 1998 May;157(5 Pt 1):1489-97
pubmed: 9603128
Eur Respir J. 2004 Jun;23(6):832-40
pubmed: 15218994
Chest. 2005 Sep;128(3):1168-78
pubmed: 16162703
COPD. 2014 Apr;11(2):190-6
pubmed: 24377907